Phase II trials of cisplatin and piperazinedione as single agents in the treatment of advanced or recurrent non-squamous cell carcinoma of the cervix

A Gynecologic Oncology Group Study

J. T. Thigpen, J. A. Blessing, W. C. Fowler, Kenneth D Hatch

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

A total of 42 patients with advanced or recurrent carcinoma of the cervix, other than squamous cell carcinoma, were entered onto two phase II studies by the Gynecologic Oncology Group. Of 16 patients registered to receive piperazinedione at a dose of 9 mg/m2 iv every 3 weeks, two were inevaluable for response because of the lack of measurable disease. Of the remaining 14, two (14%) had complete response. Adverse effects were limited to myelosuppression, nausea and vomiting, and nephrotoxicity. Among 26 patients registered to receive cisplatin, three were deemed ineligible and three were inevaluable for the study. Of the remaining 20 patients, one (5%) had complete response and three (15%) had partial response. Primary adverse effects included myelosuppression, frequent nausea and vomiting, and nephrotoxicity. The most common histologic subtypes noted adenocarcinoma and adenosquamous carcinoma, and responses were noted among patients with each subtype on each drug. Both drugs appear to possess moderate activity against non-squamous carcinoma of the cervix.

Original languageEnglish (US)
Pages (from-to)1097-1100
Number of pages4
JournalCancer Treatment Reports
Volume70
Issue number9
StatePublished - 1986
Externally publishedYes

Fingerprint

3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione
Cervix Uteri
Cisplatin
Carcinoma
Nausea
Vomiting
Adenosquamous Carcinoma
Therapeutics
Pharmaceutical Preparations
Squamous Cell Carcinoma
Adenocarcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{99ac0e3e45964db3be0c89379cd8c561,
title = "Phase II trials of cisplatin and piperazinedione as single agents in the treatment of advanced or recurrent non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study",
abstract = "A total of 42 patients with advanced or recurrent carcinoma of the cervix, other than squamous cell carcinoma, were entered onto two phase II studies by the Gynecologic Oncology Group. Of 16 patients registered to receive piperazinedione at a dose of 9 mg/m2 iv every 3 weeks, two were inevaluable for response because of the lack of measurable disease. Of the remaining 14, two (14{\%}) had complete response. Adverse effects were limited to myelosuppression, nausea and vomiting, and nephrotoxicity. Among 26 patients registered to receive cisplatin, three were deemed ineligible and three were inevaluable for the study. Of the remaining 20 patients, one (5{\%}) had complete response and three (15{\%}) had partial response. Primary adverse effects included myelosuppression, frequent nausea and vomiting, and nephrotoxicity. The most common histologic subtypes noted adenocarcinoma and adenosquamous carcinoma, and responses were noted among patients with each subtype on each drug. Both drugs appear to possess moderate activity against non-squamous carcinoma of the cervix.",
author = "Thigpen, {J. T.} and Blessing, {J. A.} and Fowler, {W. C.} and Hatch, {Kenneth D}",
year = "1986",
language = "English (US)",
volume = "70",
pages = "1097--1100",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Phase II trials of cisplatin and piperazinedione as single agents in the treatment of advanced or recurrent non-squamous cell carcinoma of the cervix

T2 - A Gynecologic Oncology Group Study

AU - Thigpen, J. T.

AU - Blessing, J. A.

AU - Fowler, W. C.

AU - Hatch, Kenneth D

PY - 1986

Y1 - 1986

N2 - A total of 42 patients with advanced or recurrent carcinoma of the cervix, other than squamous cell carcinoma, were entered onto two phase II studies by the Gynecologic Oncology Group. Of 16 patients registered to receive piperazinedione at a dose of 9 mg/m2 iv every 3 weeks, two were inevaluable for response because of the lack of measurable disease. Of the remaining 14, two (14%) had complete response. Adverse effects were limited to myelosuppression, nausea and vomiting, and nephrotoxicity. Among 26 patients registered to receive cisplatin, three were deemed ineligible and three were inevaluable for the study. Of the remaining 20 patients, one (5%) had complete response and three (15%) had partial response. Primary adverse effects included myelosuppression, frequent nausea and vomiting, and nephrotoxicity. The most common histologic subtypes noted adenocarcinoma and adenosquamous carcinoma, and responses were noted among patients with each subtype on each drug. Both drugs appear to possess moderate activity against non-squamous carcinoma of the cervix.

AB - A total of 42 patients with advanced or recurrent carcinoma of the cervix, other than squamous cell carcinoma, were entered onto two phase II studies by the Gynecologic Oncology Group. Of 16 patients registered to receive piperazinedione at a dose of 9 mg/m2 iv every 3 weeks, two were inevaluable for response because of the lack of measurable disease. Of the remaining 14, two (14%) had complete response. Adverse effects were limited to myelosuppression, nausea and vomiting, and nephrotoxicity. Among 26 patients registered to receive cisplatin, three were deemed ineligible and three were inevaluable for the study. Of the remaining 20 patients, one (5%) had complete response and three (15%) had partial response. Primary adverse effects included myelosuppression, frequent nausea and vomiting, and nephrotoxicity. The most common histologic subtypes noted adenocarcinoma and adenosquamous carcinoma, and responses were noted among patients with each subtype on each drug. Both drugs appear to possess moderate activity against non-squamous carcinoma of the cervix.

UR - http://www.scopus.com/inward/record.url?scp=0022512358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022512358&partnerID=8YFLogxK

M3 - Article

VL - 70

SP - 1097

EP - 1100

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 9

ER -